Pharmacist Moms Group^™

In part 2 of this interview, Michael Mina, MD, PhD, discusses LIBERTY study data showing that VYD2311 boosted neutralizing activity without interfering with mRNA COVID-19 vaccine response.

Justin Arnall, PharmD, BCOP, Breanna Taylor, PharmD, BCOP, and Jeff Goff, RPh, MS, discuss how expanding IV iron indications across cardiology, oncology, and CKD are reshaping the pharmacist's role in formulary strategy, product stewardship, and patient identification.

In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, discuss how an investigational meditope-enabled CAR T-cell platform could offer control through adapter dosing and the pharmacist’s role in its clinical development.

When even federal guidance sparks debate, an expert advises pharmacists to consider the source and point patients to long-standing healthful eating.

In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, discuss preclinical research on a meditope-enabled platform designed to redirect CAR T cells toward additional tumor targets and support their expansion after infusion.

Panelists explain how health systems can use the National Kidney Foundation’s CKDintercept initiative to build interdisciplinary, value-based kidney care, starting with small patient groups and setting time-bound treatment goals.

The cardiovascular-kidney-metabolic (CKM) framework can replace siloed care with comanagement across specialties, centered on an engaged patient and supported by making fuller use of clinical pharmacists.

The cardiovascular-kidney-metabolic framework puts the urine albumin-to-creatinine ratio at the center of risk stratification, so that a positive result leads to earlier treatment rather than just being documented.

A panel of 4 health care professionals describe how their health systems adopted the race-free 2021 CKD-EPI equations.